HealthTech Bio Actives (HTBA), a specialist in flavonoids and active forms of vitamin B12, has announced the construction of a new diosmin production plant at its research, development, and manufacturing center in Murcia, Spain. The €6 million investment will increase diosmin production capacity by 40%, supporting its growth plans.

Diosmin, a citrus flavonoid, is associated with improvements in venous tone, circulation, and vascular discomfort, HTBA noted. The supplier, which reports to be the world’s largest producer of diosmin, manufactures it as an active pharmaceutical ingredient for the treatment of chronic cardiovascular disease, varicose veins, spider veins, and hemorrhoids. It also produces DiosVein, a dietary supplement ingredient, to support healthy legs.

“This latest investment further reinforces HTBA’s standing as an international leader in the production of flavonoids, supporting innovation in the health and wellness sector,” said Alexandre Valls-Coma, CEO. “By prioritizing innovation and sustainable manufacturing, over the last few years the company has entered a period of remarkable growth. This project further strengthens our expansion and competitiveness in a highly regulated and demanding global environment.”

HTBA produces diosmin via a solvent-free manufacturing process that yields no remaining organic solvents. The new manufacturing plant consolidates HTBA’s position as the only diosmin manufacturer that uses water as a solvent, the company reported. HTBA recently received a zero waste certification granted by AENOR, verifying that the company valorizes at least 90% of the waste it generates, preventing it from ending up in a landfill.

“We’re always striving to achieve better solutions and processes that improve manufacturing sustainability and efficiency while helping to support health and well-being,” said Ignacio Paco Ferreira, COO. “Our new plant will not only increase production, it will also equip us to improve our operating model through research-driven process innovation, digitalization, and energy efficiency. With improved and expanded production, we’re gearing up to better meet customer and consumer needs for the long-term, offering consistent, reliable supply as a trusted source of high-quality diosmin for nutraceutical and pharmaceutical applications.”

Earlier this year, HTBA also invested €25 million to modernize its research, development, and manufacturing center in Spain. This included the construction of a new production plant which made HTBA the only company in Europe capable of producing all active forms of vitamin B12, the company reported.